Discounted Cash Flow
Immunitybio, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $44.0k | $-120.8m | $-45.2m | -274565.9% | $-1.47 |
| 2017 | $45.0k (2.3%) | $-96.4m (20.2%) | $-83.6m (-85.1%) | -214273.3% (22.0%) | $-1.20 (18.4%) |
| 2018 | $47.0k (4.4%) | $-96.2m (0.2%) | $-76.5m (8.5%) | -204736.2% (4.5%) | $-1.22 (-1.7%) |
| 2019 | $43.0k (-8.5%) | $-65.8m (31.6%) | $-65.5m (14.3%) | -152997.7% (25.3%) | $-0.70 (42.6%) |
| 2020 | $111.0k (158.1%) | $-92.4m (-40.4%) | $-73.1m (-11.5%) | -83227.9% (45.6%) | $-0.89 (-27.1%) |
| 2021 | $934.0k (741.4%) | $-346.8m (-275.4%) | $-308.0m (-321.4%) | -37129.6% (55.4%) | $-0.89 (0.0%) |
| 2022 | $240.0k (-74.3%) | $-416.6m (-20.1%) | $-415.7m (-35.0%) | -173569.6% (-367.5%) | $-1.04 (-16.9%) |
| 2023 | $622.0k (159.2%) | $-583.2m (-40.0%) | $-397.3m (4.4%) | -93761.4% (46.0%) | $-1.15 (-10.6%) |
| 2024 | $14.7m (2270.6%) | $-413.6m (29.1%) | $-398.1m (-0.2%) | -2804.8% (97.0%) | $-0.59 (48.7%) |
| 2025 | $113.3m (668.3%) | $-351.4m (15.0%) | $-308.8m (22.4%) | -310.2% (88.9%) | $-0.38 (35.6%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.